Cargando…

CXCR4 antagonists for treatment of breast cancer

Detalles Bibliográficos
Autores principales:	Cortés, Javier, Holgado, Esther, Perez-Garcia, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173365/ https://www.ncbi.nlm.nih.gov/pubmed/30323888 http://dx.doi.org/10.18632/oncotarget.26090

Ejemplares similares

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis
por: Hawkins, Oriana E, et al.
Publicado: (2012)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
por: Pérez-García, José, et al.
Publicado: (2012)

Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells
por: Huang, Ming-Bo, et al.
Publicado: (2018)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

Calcineurin/CXCR4 in T-ALL
por: Passaro, Diana, et al.
Publicado: (2015)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation
por: Zhou, Jun, et al.
Publicado: (2020)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis
por: Hernandez, Lorena, et al.
Publicado: (2011)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo
por: Ling, Xiaoyang, et al.
Publicado: (2013)

Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
por: Guo, Hua, et al.
Publicado: (2017)

Self-assembly of CXCR4 antagonist peptide–docetaxel conjugates for breast tumor multi-organ metastasis inhibition
por: Li, Chen, et al.
Publicado: (2023)

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
por: Batista, Marta Vaz, et al.
Publicado: (2023)

HPMA Copolymer CXCR4 Antagonist Conjugates Substantially Inhibited the Migration of Prostate Cancer Cells
por: Peng, Zheng-Hong, et al.
Publicado: (2014)

CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members
por: Guo, Kaibo, et al.
Publicado: (2019)

An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
por: Harms, Mirja, et al.
Publicado: (2021)

CXCL12-CXCR4 axis in feline mammary carcinoma
por: Ferreira, Fernando
Publicado: (2017)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t
por: Ward, Richard J., et al.
Publicado: (2020)

Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas
por: González-Arriagada, Wilfredo Alejandro, et al.
Publicado: (2022)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

Genetic Polymorphism and Expression of CXCR4 in Breast Cancer
por: Okuyama Kishima, Marina, et al.
Publicado: (2015)

Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer
por: Bumpers, Harvey, et al.
Publicado: (2013)

Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers
por: Katkoori, Venkat R., et al.
Publicado: (2015)

Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
por: Kim, Joseph, et al.
Publicado: (2012)

New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
por: D’Alterio, Crescenzo, et al.
Publicado: (2020)

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
por: Koenig, Lars M., et al.
Publicado: (2020)

Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro
por: Kim, Ha-Yon, et al.
Publicado: (2011)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8vhka1b0tnthnj616hhuuk5rn0